Is immunogen (IMGN) stock a buy or sell?
ImmunoGen has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $9.50, ImmunoGen has a forecasted upside of 44.6% from its current price of $6.57.
Where can I buy IMGN shares?
Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Who sold IMGN stock in the last quarter?
IMGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Healthcare of Ontario Pension Plan Trust Fund, Two Sigma Advisers LP, Two Sigma Investments LP, Wellington Management Group LLP, Morgan Stanley, Dimensional Fund Advisors LP, and Citigroup Inc..
Should I buy or sell ImmunoGen stock right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings an...
What is ImmunoGen's stock price forecast for 2022?
4 Wall Street analysts have issued 12-month price targets for ImmunoGen's stock. Their forecasts range from $5.00 to $18.00. On average, they predi...
How has ImmunoGen's stock price performed in 2022?
ImmunoGen's stock was trading at $7.42 on January 1st, 2022. Since then, IMGN shares have decreased by 54.3% and is now trading at $3.39. View the...
Are investors shorting ImmunoGen?
ImmunoGen saw a decrease in short interest in May. As of May 31st, there was short interest totaling 15,910,000 shares, a decrease of 16.5% from th...
When is ImmunoGen's next earnings date?
ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022. View our earnings forecast for ImmunoGen .
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings data on Friday, May, 6th. The biotechnology company reported ($0.10) earnings per sha...
What guidance has ImmunoGen issued on next quarter's earnings?
ImmunoGen issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the...
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the following people: Mr. Mark Joseph Enyedy , Pres, CEO & Director (Age 58, Pay $1.24M) Ms. Susan Altschul...
What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?
16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com . Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.
About ImmunoGen
ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
What is immunogen in medicine?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock. View analyst ratings for ImmunoGen or view top-rated stocks.
What is transparency in investing?
Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
Does Morningstar cover ratings?
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
